The Indian Pharmacopoeia (IP) 2026 has become the first pharmacopoeia globally to introduce exclusive quality standards for blood and blood components, marking a significant step towards enhancing patient safety and quality assurance in transfusion services.
A pharmacopoeia serves as an official reference document that sets quality standards for medicines and healthcare products manufactured, imported, sold, or distributed within a country. These standards help ensure the identity, purity, strength, and overall quality of products.
The newly introduced standards were highlighted during a national conference organized by the Indian Pharmacopoeia Commission (IPC) at its campus in Ghaziabad. The event aimed to create awareness and support the implementation of the new monographs related to blood and blood components in IP 2026.
Addressing the conference virtually, Harsh Mangla, Joint Secretary (Drug and Food Regulation) in the Union Health Ministry, described the inclusion of these standards as a landmark achievement, noting that no other pharmacopoeia currently provides dedicated standards for blood and blood components. He also urged stakeholders to collaborate in ensuring the quality, safety, and availability of blood products across the country.
The conference was attended by more than 160 participants, including professionals from blood centres, quality assurance and quality control officers, state licensing authorities, haemovigilance experts, and government health officials from Uttar Pradesh, Rajasthan, Uttarakhand, Haryana, Punjab, and Madhya Pradesh.
IPC Secretary-cum-Scientific Director Dr. V. Kalaiselvan stated that the newly added standards are aligned with current scientific advancements and national as well as international regulatory requirements. He said they would strengthen quality assurance, improve patient safety, and support regulatory compliance in transfusion services.
Technical sessions during the conference covered topics such as IP 2026 standards for blood and blood components, regulatory requirements, rational use of blood, plasma quality, the National Formulary of India, the Haemovigilance Programme of India, and IP Online.
Experts from the IPC, state licensing authorities, haemovigilance programmes, and transfusion medicine institutions also participated in a panel discussion on implementation strategies and emerging regulatory expectations.
According to officials, the conference provided a platform for stakeholder engagement and capacity building, helping blood centres prepare for the effective adoption of the new standards and ultimately improving the quality, safety, and efficacy of blood and blood components nationwide.